The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Update of tacrolimus in clinical kidney transplantation
Author(s): 
Pages: 134-140
Year: Issue:  3
Journal: World Clinical Drugs

Keyword:  tacrolimuskidney transplantationpharmacogeneticsrational drug use;
Abstract: The calcineurin inhibitor-tacrolimus has become the first-line immunosuppressant in clinical kidney transplantation. However, the adverse reactions of tacrolimus such as nephrotoxicity and metabolism disorders affect longterm outcome of kidney transplantation. This review focuses the updates of tacrolimus in kidney transplantation to minimize or avoid tacrolimus in new immunosuppressive regimens which involved sirolimus, everolimus, protein kinase C inhibitor(sotrastaurin), Janus kinase-3 inhibitor(CP-690550) or CTLA-4 fusion protein(belatacept).
Related Articles
No related articles found